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Abstract
The controlled delivery of antibiotics, anti-inflammatory agents, or chemotherapeutic agents to 
the periodontal site is a recognized strategy to improve the efficiency of regenerative processes of 
hard tissues. A novel approach based on the trapping of tetracycline hydrochloride–loaded particles 
in polycaprolactone nanofibers was used to guide the regeneration processes of periodontal 
tissue at the gum interface. Chitosan nanoparticles loaded with different levels of tetracycline 
hydrochloride (up to 5% wt) were prepared by solution nebulization induced by electrical forces 
(i.e. electrospraying). The fine tuning of process parameters allows to obtain nanoparticles with 
tailored sizes ranging from 0.485 ± 0.147 µm to 0.639 ± 0.154 µm. The tetracycline hydrochloride 
release profile had a predominant burst effect for the first 70% of release followed by a relatively 
slow release over 24 h, which is promising for oral drug delivery. We also demonstrated that 
trapping tetracycline hydrochloride–loaded particles with submicrometer diameters into a 
polycaprolactone fiber network contributed to slowing the release of tetracycline hydrochloride 
from the nanoparticles, thus providing a more prolonged release in the periodontal pocket during 
clinical therapy. Preliminary studies on human mesenchymal stem cells confirm the viability of 
cells up to 5 days after culture, and thereby, validate the use of nanoparticle-/nanofiber-integrated 
systems in periodontal therapies.
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Introduction
Periodontal diseases are pathologies affecting the supporting tissues of the teeth. The most com-
mon are gingivitis and periodontitis.1–3 Gingivitis is nondestructive with the formation of gram-
positive bacterial biofilms (bacterial plaque), which strongly adhere to teeth surfaces.4 Clinical 
signs include swelling, spontaneous redness, and bleeding gum tissue after brushing. Periodontitis 
(chronic and aggressive) is the most common periodontal pathology, affecting up to 70% of the 
global population, and requiring restituto in integrum to preserve the quality of life of the patient. 
This destructive pathology is mainly caused by gram-negative anaerobic bacteria hosted by the 
peridontium—that is, gingiva, cementum, alveolar bone, and periodontal ligament. It is the result 
of a complex bacteria–host response in genetically susceptible patients, in which inflammation 
stimulates the gingival epithelium to migrate along the tooth surface, so forming the “periodontal 
pocket.” The periodontal pocket provides an ideal site for the growth and proliferation of microor-
ganisms, which cause the loss of connective tissue and progressive breakdown of alveolar bone.5 
In the presence of an intraosseous bone defect, guided tissue regeneration using barrier membranes 
can be the preferred approach to obtain new periodontal attachment.6,7 The surgical implantation of 
periodontal pockets may be associated with infection and inflammation,8 which can adversely 
affect the natural progress of tissue regeneration. Controlled delivery of antimicrobials or antibiot-
ics is a promising therapy to prevent and/or treat tissue infection during periodontal surgery,9 
whereas time-controlled release of anti-inflammatory or chemotherapeutic agents in the periodon-
tal site is strongly indicated for improved efficiency of tissue regeneration.1
It is extremely important to design carriers able to selectively deliver agents into the periodontal 
pocket at therapeutic levels10 to reduce probing depths, more efficiently stabilize tissue interfaces, 
and minimize bleeding.9
Several recent studies focused on the fabrication of chitosan (CHI) nanoparticles by an electro-
spraying technique to form drug delivery carriers that have interesting preliminary results.11–13 In 
particular, the electrospraying process may influence the morphology of polymer particles, just as 
the electrospinning process has been reported to have an influence on fiber morphology.14 
Electrospraying is compatible with most common drugs used in local delivery, such as tetracycline, 
doxycycline, minocycline, metronidazole, and chlorhexidine.9,15,16 Among these, tetracycline 
hydrochloride (TCH) is the chemical agent most frequently used as an antibiotic in the treatment 
of periodontal diseases. Clinical studies have shown that TCH has an effective spectrum of activity 
against many of the anaerobic microbes associated with periodontitis patients.17 Alternatively, 
periodontal membranes have been fabricated by including nanosized hydroxyapatite particles as 
osteoconductive/inductive signals and metronidazole in poly (dl-lactide-co-ε-caprolactone) 
(PLCL) films to fight periodontal pathogens.17 Here, multilayered electrospun systems composed 
of protein/polymer ternary blends have recently been developed by coelectrospinning to obtain 
periodontal barriers for periodontal implants.17–20
In this work, we propose a novel approach, based on the simultaneous use of electrospinning 
and electrospraying techniques, to design integrated membranes that entrap nanoparticles in 
nanofiber networks for periodontal surgery. Although the idea of using electrospun fibers has been 
previously investigated for hard tissue applications,21–27 the novelty of this work lies in the intro-
duction of a reliable and efficient method integrating polymeric carriers in nanofibrous membranes 
for local drug delivery. In particular, the setup configuration is simple and versatile, requiring the 
simultaneous injection of solution from two different nozzles. It is possible to control the spatial 
arrangement of fibers by setting the head motion and collectors. In this work, we propose an inte-
grated system comprising electrospun polycaprolactone (PCL) fibers and TCH-loaded CHI parti-
cles—produced via electrospraying—to be anatomically adapted at the interface between alveolar 
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bone and epithelial tissue. It is essential that the integrated periodontal membranes preserve their 
structural, dimensional, and mechanical integrity long enough to permit periodontal regeneration. 
The use of PCL ensures the creation of a fiber network with suitable properties in terms of degra-
dability and biocompatibility to meet this prerequisite.28 The entrapment of TCH-loaded CHI nan-
oparticles among the nanofibers also provides a controlled release of drug that prevents inflammation 
in the periodontal pocket.29
Materials and methods
Materials
Poly(ε-caprolactone) pellets (PCL; Mn: 45,000 kDa) and CHI (viscosity: 20–300 cP, 1% in 1% 
acetic acid) were purchased from Sigma–Aldrich (Milan, Italy). Methylene chloride (MC) and 
methanol were purchased from Sigma–Aldrich for use as solvent and cosolvent in the preparation 
of PCL solutions. Acetic Acid (pure analytical grade) from JT Baker (Milan, Italy) was used to 
dissolve CHI. All other chemicals used were analytical grade. TCH was obtained from Sigma–
Aldrich and used without any purification.
Fabrication of TCH-loaded CHI particles using electrospraying
CHI powder was dissolved in 90% (v/v) acetic acid solution to form 2% (w/v) CHI solution. CHI 
solution was gently stirred for 2 days at room temperature until the CHI powder was completely 
dissolved. TCH—from 1% to 5% w/w with respect to the polymer—was added in 2% (w/v) CHI 
solution and stirred until complete dissolution of the drug. The TCH-loaded CHI solution has a 
dark yellow appearance.
The electrospraying process was carried out by using a NANON 01 system (MECC, Japan). 
Process parameters, that is, voltage, flow rate, and tip/collector distance were varied individually 
in order to optimize the particle morphology. Aluminum foil was used as a conductive collector 
plate. All the samples were dried overnight in a fume hood and used for the next step.
Fabrication of integrated particle/fiber membranes
PCL pellets were dissolved in MC/methanol (1:1 v/v) to form a clear and homogenous solution 
(10% w/v). TCH-loaded CHI solution (2% w/v) with a TCH concentration ranging from 1%–5% 
w/w with respect to polymer fraction was used for TCH-loaded nanoparticles. Integrated systems 
were obtained via simultaneous deposition by electrospinning and electrospraying using two sepa-
rate nozzles in the same spinneret (schematically illustrated in Figure 1) by using the electrospin-
ning equipment. Two different flow rates—0.1 mL/h for TCH-loaded CHI solution and 0.5 mL/h 
for PCL solution—were used. Moreover, a voltage of 16 kV was imposed at both tips placed at a 
collector distance of 10 cm. The spinneret, which contains both nozzles, was translationally moved 
(5 mm/s) along 100 mm width to improve fiber and particle homogeneity. All samples were dried 
overnight in a fume hood before use.
Morphological studies
The morphology of TCH-loaded CHI particles and integrated membranes—PCL nanofibers with 
TCH-loaded CHI particles—was investigated by scanning electron microscopy (SEM). The sam-
ples were deposited onto gold-coated stubs and analyzed by field emission SEM (Quanta 200 FEI, 
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The Netherlands). Fiber and particle average diameters were estimated by using Image J software, 
(version 1.37) on 20 random sample images at the same magnification.
In vitro drug release studies
Encapsulation efficiency and loading capacity of TCH-loaded CHI particles and integrated mem-
branes (PCL nanofibers with CHI particles) were studied. In particular, the amount of free drug 
released was determined by ultraviolet (UV) spectrophotometry (Cary 100 Varian, Italy). Before 
UV measurements, samples were centrifuged at 5000 g for 30 min. A linear calibration curve with 
different concentrations of TCH in phosphate buffer saline (PBS) (pH 7.4) was established to find 
the correlation between the absorbance and the drug concentration.
TCH-loaded CHI particles and integrated fiber/particle membranes were dipped into 35 mL 
PBS (pH 7.4) at 37°C ± 0.5°C. Before testing, all the samples were mixed using a vortex for 2–3 
min. A portion of the solution (1 mL) was analyzed using a UV visible spectrophotometer at λmax 
of 380 nm. The detected UV absorbances of TCH were reported in terms of concentration accord-
ing to the calibration curve of TCH in the buffer. Then, the relative amount of the released TCH 
was calculated as a function of the incubation time. A graph was plotted for cumulative release of 
TCH (%) versus time (hours).
The encapsulation efficiency and drug loading were calculated using the following relations:
EE (Encapsulation Efficiency) = (m − mf)/m
where m is the total TCH amount and mf is the free amount of TCH
LC (Loading Capacity) = m − mf/mc
where mc is the total amount of CHI.
Figure 1. Scheme of the CHI particle trapping procedure by the simultaneous use of electrospinning and 
electrospraying technique.
CHI: chitosan; PCL: polycaprolactone.
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Cell culture
Biological assays were performed using a human mesenchymal stem cell (hMSC) line obtained 
from Lonza (Milan, Italy). hMSCs were cultured in 75-cm2 cell culture flasks in Eagle’s alpha 
minimum essential medium (α-MEM) supplemented with 10% fetal bovine serum, antibiotic solu-
tion (streptomycin 100 µg/mL and penicillin 100 U/mL; Sigma–Aldrich), and 2 mM l-glutamine. 
Cells were incubated at 37°C in a humidified atmosphere with 5% CO2 and 95% air. Four to six 
passages of hMSCs were used for all the experimental procedures.
Cell morphology
The cell morphology and cell spreading pattern interaction of hMSC cultured onto TCH-loaded 
CHI particles and integrated PCL/CHI membranes were evaluated by confocal laser scanning 
microscopy (LSM 510, CarlZeiss). Briefly, hMSCs (1 × 103 cells) were incubated for 24 h, and 
nonadherent cells were removed by rinsing three times with PBS. Scaffolds were then incubated 
with CellTrackerTM Green CMFDA (5-Chloromethylfluorescein Diacetate)  in phenol red–free 
medium at 37°C for 30 min. Subsequently, the cell culture was washed with PBS and incubated for 
1 h in complete medium prior to the LSM visualization.
Cytotoxicity test
To indirectly assess cytotoxicity in hMSC cultures, TCH-loaded CHI particles and integrated PCL/
CHI membranes were put onto 24-well cell culture plates in triplicate and incubated after adding 1 
mL of α-MEM basal complete media to each well. After 1, 3, and 5 days, media were removed, and 
500 µL of the media that was in direct contact with the samples were added into 24-well cell culture 
plates previously seeded with (1.2 × 104) hMSCs. The hMSC cultures were then removed and 
washed twice with PBS. A quantity of 500 µL of the media, which was previously in direct contact 
with the TCH-loaded CHI particles and integrated PCL/CHI membranes, was added to the hMSC 
cultures. The cell culture plates were further incubated at 37°C, with 5% CO2 and 95% air humid-
ity, for 1, 3, and 5 days. Indirect cytotoxicity response was validated by the (3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. This assay is based on the ability of 
mitochondrial dehydrogenases of living cells to oxidize a tetrazolium salt (MTT) to an insoluble 
blue formazan product. The concentration of the blue formazan product is directly proportional to 
the number of metabolically active cells. The hMSCs were washed with PBS and incubated with 
fresh culture medium containing 0.5 mg/mL of MTT for 4 h at 37°C in the dark. The supernatant 
was removed and dimethyl sulfoxide (DMSO) was added. After slow shaking (60 min), the absorb-
ance was quantified by spectrophotometry at 570 nm with a plate reader. The culture medium was 
renewed every day.
Cell proliferation
The hMSCs (1.6 × 104 cells) were plated onto TCH-loaded CHI particles and PCL-/CHI-integrated 
membranes. Cell proliferation was evaluated by the Alamar Blue assay (AbD Serotec Ltd, UK) for 
7, 14, and 21 days of culture. This assay allows quantification of the fluorescence of the product 
formed from reduction by mitochondrial enzymes such as flavin mononucleotide dehydrogenase, 
flavin adenine dinucleotide dehydrogenase, and nicotinamide adenine dinucleotide dehydroge-
nase. Redox product levels also gave quantitative indications about metabolic activity of living 
cells. Alamar Blue (1 mL) was diluted in phenol red–free medium (1:10) according to the manu-
facturer’s protocol, and cells were incubated for 4 h at 37°C, with 5% CO2. Afterward, the solution 
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(100 µL) was transferred into a 96-well plate for colorimetric analyses. Cell-free plates were used 
to correct any background interference from the redox indicator. The optical density was immedi-
ately measured by a spectrophotometer (Sunrise; Tecan, Männedorf, Zurich, Switzerland) at wave-
lengths of 540 and 600 nm.
Statistical analysis
All numerical data are presented as mean ± standard deviation. All results were subjected to statis-
tical evaluation using an unpaired Student’s t-test to determine significant differences between 
groups. The significance level was set at p < 0.05.
Results and discussion
TCH-loaded CHI particles
Electrospraying was used to produce nanoparticles. The charge and size of the particles were con-
trolled to some extent by electrical forces—that is, by adjusting flow rate and voltage applied to the 
nozzle.30 According to Arya et al.,11 spherical CHI particles have been prepared using 90% (v/v) 
acetic acid solution, which provided optimal viscosity for jet breaking induced by electrical forces. 
This arises from the particular effects of acetic acid concentration on the conductivity13 and surface 
tension.31 The low degree of dissociation of acetic acid ensures moderate conductivity and viscos-
ity properties that enhance the stabilization of the electrospraying process.
In this study, the feasibility of preparing TCH-loaded CHI particles by electrospraying was 
investigated at different levels of TCH. The relative TCH amount affects the morphology and the 
average size of CHI particles, as reported in Figure 2. By loading in 1% w/w TCH, the CHI 
formed a monodisperse distribution of clustered particles with an average individual diameter of 
803 ± 128 nm (Figure 2(e)). As the TCH loading increased to 3% and 5% w/w, a more heterogene-
ous distribution of particle sizes and a decrease in particle diameters was observed. The use of 
nanosized particles with high surface area generally promoted a uniform release of the encapsu-
lated drug, which made them useful for mucosal or nasal delivery. In addition, confirmed by 
several studies, the suitability of CHI as a drug carrier has been demonstrated by its excellent 
mucoadhesive properties.32
The biodegradable properties of CHI-based systems enable highly tunable drug release for 
treatment of different diseases as a function of specific drugs and polymer formulations.15 However, 
the use of different microencapsulation techniques may influence the kinetics of drug release from 
micro-/nanoparticles.8,10,29 Therefore, we used electrically assisted techniques to prepare TCH-
loaded CHI micro-/nanoparticles for short-term TCH release, as shown in Figure 3. The TCH 
release curve has a rapid initial burst during the first 3 h, followed by a prolonged drug release that 
occurs during the next 4 h. Also, the release rate increased as the concentration of TCH increased.
Antibiotic release is primarily driven by the fluid diffusion through the particle matrix. In this 
case, rapid dissolution of particles produces a kinetic profile with a large initial burst region. 
This is a positive attribute, in that the initial burst release is often required to achieve a sufficient 
initial dosage capable of eliminating intruding bacteria before they begin to proliferate.33 This 
burst release was ascribable to a preferential drug distribution on the particle surface. The TCH 
diffused easily during the first stage of the incubation, supported by the fast degradation of CHI 
particles as reported previously.34 The drug dissolution was also facilitated by the hydrophilic 
nature of CHI, which allowed rapid penetration of water into the particles. While the 
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Figure 2. TCH-loaded CHI nanoparticles via electrospraying techniques: (a–d) SEM images of particles 
with different TCH loading; (a) 0%, (b) 1%, (c) 3%, and (d) 5% w/w (magnification 15kx, scale bar = 5 µm) 
and (e) particle size average diameter versus % (w/w) TCH concentration by image analysis.
TCH: tetracycline hydrochloride; CHI: chitosan.
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encapsulation efficiency and drug loading are invariant with TCH concentration, the drug release 
rate seemed to be dependent upon the relative amount of TCH used (Figure 3). Indeed, the 1%, 
3%, and 5% w/w TCH-loaded CHI particles had a high encapsulation efficiency of 97.8%, 
98.1%, and 98.0%, respectively. The measured drug amount was approximately 0.97%, 2.9%, 
and 4.9% for 1%, 3%, and 5% w/w fractions, respectively. At higher TCH concentrations, the 
hydrophilic nature of TCH and its high water solubility tend to promote the formation of molec-
ular clusters that were not physically bound to the polymer but were entrapped in the polymer 
network.34,35 Consequently, TCH-loaded particles with higher drug concentration had faster drug 
release.
The fluorescent images obtained by confocal microscopy of TCH-loaded CHI micro-/nanopar-
ticles with cells are presented in Figure 4. The green staining indicated that hMSCs were vital to 
the direct contact of TCH with independent CHI particles on TCH loading (Figure 4(a) to (d)). In 
particular, an improved cell growth is apparent in the case of 1% TCH CHI particles, where 
spindle-like cell shapes were detected with extended and aligned filopodia. In contrast, the cells 
spread without any orientation preference in the case of CHI particles with 5% TCH. This evi-
dence is supported by the indirect MTT and Alamar Blue reduction tests (Figure 5(a) and (b)) for 
samples with different TCH loading. After 1, 3, and 5 days of hMSC exposure to the eluent, the 
cell activity was progressively reduced with increased amounts of TCH, indicating a cytotoxic 
effect of TCH.
TCH-loaded CHI particles and PCL nanofiber–integrated membranes
The development of integrated fiber/particle systems opens an interesting route to fabricate mem-
branes with tunable physico-chemical, mechanical, and biological properties that could lead to 
more efficacious periodontal regeneration. The electrospinning and electrospraying technique 
used simultaneously to produce nonwoven PCL fibers can entrap TCH-loaded CHI particles 
Figure 3. TCH release profiles from CHI particles with different TCH loading at 37°C.
TCH: tetracycline hydrochloride: CHI: chitosan.
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(Figure 6). The setup requires the use of two different nozzles, working at the same voltage but 
different flow rates.
Moving the head spinneret during spinning (at approximately 5 mm/s) has also been used to 
balance the evaporation phenomena, which occurs during simultaneous spinning. This motion pro-
motes solvent evaporation from PCL solution due to higher MC volatility. The MC volatility also 
promotes surface roughening of PCL fibers. In contrast, the acetic acid evaporation does not occur 
completely, but solvent traces still reside in CHI particles before their deposition. This promotes 
chemical anchorage of the particles on the PCL fiber surface (Figure 6), which could be relevant 
for the prevention of any transmembrane crossing of CHI particles during in vitro culture, thus 
affecting specific cell activities.36
The effect of the process parameters, such as voltage and flow rate, was investigated with the 
aim of optimizing fiber and particle morphology. Image analysis data for PCL/CHI membranes 
produced at three different voltages (14, 16, and 17 kV) and constant flow rate (0.3 
Figure 4. Biocompatibility of TCH-loaded CHI particles: confocal images of CHI particles with different 
TCH loading—(a) 0%, (b) 1%, (c) 3%, and (d) 5% (w/w).
TCH: tetracycline hydrochloride; CHI: chitosan.
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mL/h) are presented in Figure 7(a). The PCL fibers and CHI particles had comparable average 
diameters—0.601 µm and 0.642 µm, respectively—at the lowest applied voltage (14 kV). The 
increase of voltage up to 17 kV increased the particle size to 0.680 µm. Notably, an increased volt-
age also promoted jet instability, resulting in a wide fiber diameter distribution, from 0.549 to 
0.788 µm,14 as voltage increased. A comparison of PCL/CHI membranes prepared at different flow 
rates is presented in Figure 7(b). PCL fibers show a slight reduction of fiber diameter from 0.567 
to 0.491 µm as the flow rate decreases from 0.1 to 0.3 mL/h. Similarly, TCH-loaded CHI particles 
show a greater reduction in size from 0.712 to 0.519 µm. Notably, a decrease in CHI particle popu-
lation on the surface of PCL fibers is detected as the voltage and flow rate increase. This indicated 
Figure 5. (a) MTT assay and (b) Alamar Blue reduction versus time of culture of TCH-loaded CHI 
particles.
MTT: (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; TCH: tetracycline hydrochloride; CHI: chitosan.
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that the simultaneous deposition of particles with PCL fibers may affect CHI particle formation, as 
confirmed by the presence of fewer particles and associated spatial heterogeneity.
Figure 6. SEM (magnification 20 k×, scale bar = 5 µm) of TCH-loaded (3% w/w) CHI particles trapped in 
PCL fibers by simultaneous electrospraying/electrospinning technique.
SEM: scanning electron microscopy; CHI: chitosan; PCL: polycaprolactone; TCH: tetracycline hydrochloride.
Figure 7. Image analysis of PCL fibers and TCH-loaded CHI particles. Estimation of the characteristic 
diameter as a function of (a) voltage, (b) flow rate, and (c) TCH-loading amount.
CHI: chitosan; PCL: polycaprolactone; TCH: tetracycline hydrochloride.
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The effect of TCH concentration on the final morphology of CHI particles is shown in Figure 
7(c). Monodispersed particles with average size of 0.712 µm are obtained in the case of 1% w/w 
TCH. As the TCH concentration rises up to 5% w/w, TCH-loaded CHI particle size decreases 
down to 0.485 µm. These data indicated a higher tendency of TCH to form clusters at high concen-
trations, which favors the interaction among CHI chains during particle formation.
TCH release from integrated PCL/CHI membranes was studied to evaluate the role of the sur-
rounding fibrous network on the release of drug from nanoparticles. For all the samples tested, full 
encapsulation efficiency (approximately 100%) was calculated, independent of TCH content, as 
required in controlled drug release studies. The release profiles of CHI particles and PCL/CHI 
membranes containing 1%, 3%, and 5% w/w TCH are reported in Figure 8.
All the profiles have an initial burst release during the first 30 min, followed by a prolonged 
release in agreement with release profiles of CHI particles as shown in the case of CHI particles 
alone (Figure 3). Comparative analysis of the release mechanisms revealed slower release 
kinetics from CHI particles within a fibrous PCL network. This suggests a “retention effect” 
offered by the PCL nanofiber network on the release of highly hydrophilic TCH molecules. 
From observations of TCH release from CHI particles, the profile of integrated membranes had 
an increase in the burst effect (Figure 8), from 17% to 58% of the total released amount as the 
TCH concentration increases. The sustained release is preferentially due to the effect of nano-
particle size and shape on the depletion of the drug content, both affecting the diffusion of 
medium into particles and of TCH from the core to the surface.37 However, a slowing of the 
TCH release was detected in the case of trapped CHI particles versus CHI particles alone. This 
would provide more controlled release of drug in the periodontal pockets, where the pharma-
ceutical dose is crucial.8,38
The biological response of the TCH-loaded PCL/CHI fibers was investigated as a preliminary 
stage in their validation for clinical use. The hMSCs were evaluated in terms of cell morphology, 
growth, and phenotypic expression after in vitro culture. Confocal images of CHI/PCL fibers with 
different TCH loading are presented in Figure 9(a) to (e), with PCL nanofibers used as a control. 
Green staining is detected for all the TCH-loaded CHI/PCL fibers, indicating a higher number of 
vital cells in the presence of trapped CHI particles independent of TCH content.
Quantitative analyses (Figure 10(a) and (b)) confirm the high viability of hMSCs up to 5 days 
of culture. In particular, MTT tests and Alamar Blue reduction show a progressive decrease of cell 
proliferation during the first 5 days of culture, which confirms the negative effect of the higher 
TCH concentrations on cell response (Figure 10(b)). Based on hMSC biocompatibility results, 
TCH drug carried by CHI nanoparticles provided chemical signals that did not deleteriously affect 
cell activity, while the entrapment of CHI nanoparticles in PCL fibers promoted a more homogene-
ous and efficient distribution of the molecular signals to cells.
Conclusion
The inclusion of particles in the fiber network provided better distribution of drug into the scaf-
folds, due to the homogeneous distribution of the particles, and extended the release time of 
TCH, due to the effect of hydrophobic PCL fibers. Trapping the TCH-loaded CHI nanoparticles 
in PCL electrospun membranes was effected by simultaneous use of electrospinning and elec-
trospraying techniques. The dual nozzle system assured a homogeneous distribution of the CHI 
particles among PCL fibers. Good attachment and cell proliferation of hMSCs were observed; 
however, our studies showed hMSC cytotoxicity related to the higher TCH concentrations. 
These preliminary results are promising and encourage the future use of TCH-loaded CHI 
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Figure 8. TCH release profiles from PCL/CHI membranes with different TCH release profiles at 37°C.
CHI: chitosan; PCL: polycaprolactone; TCH: tetracycline hydrochloride.
Figure 9. hMSC response of TCH-loaded PCL/CHI membranes: (a–c) confocal images of membranes with 
different TCH loading—(a) 0%, (b) 1%, (c) 3%, and (d) 5% (w/w) and (e) PCL nanofiber control (scale bar = 
50 µm).
hMSC: human mesenchymal stem cell; CHI: chitosan; PCL: polycaprolactone; TCH: tetracycline hydrochloride.
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particles entrapped in PCL fibers for in vivo studies in human periodontal pockets. This would 
establish the efficacy of this technology as a minimally invasive approach suitable to proceed 
to clinical trials.
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